In vivo studies demonstrate that OPTN-deficient CRC cells exhibit enhanced tumor growth in immunocompetent mice, but not in immunodeficient models, highlighting its role in immune-mediated tumor control [8]. This evidence concerns the gene OPTN and neoplasm.